H.C. Wainwright increased its price target on Corcept Therapeutics (NASDAQ:CORT) shares to $115 from the previous $80, while ...
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), today announced that the US Food and Drug Administration (FDA) has ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
A groundbreaking cannabinoid-based antimicrobial, Silvanex, fights drug-resistant infections with a synergy of silver, CBC ...
Ac-SSO110 has now received FDA orphan drug designation and investigational new drug application clearance for the treatment ...
Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...
Eton Pharmaceuticals, Inc. announced that the FDA has extended the PDUFA goal date for its New Drug Application (NDA) for ET-400 to May 28, 2025, allowing the agency additional time to review ...
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at www.astellas.com. 3 Colijn JM, Liefers B ...
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...
Spinocerebellar Ataxia (SCA) is a rare, genetic, life-threatening neurodegenerative disease with no available treatment. Troriluzole demonstrated a 50-70% slowing of SCA disease progression ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results